Market Place
Sourcing Support
Amylyx Unveils Phase 3 LUCIDITY Trial For Avexitide In Hypoglycemia
04 Dec 2024 //
BUSINESSWIRE
Amylyx Pharmaceuticals to Present at Evercore ISI HealthCONx
27 Nov 2024 //
BUSINESSWIRE
Amylyx Pharma Reports Q3 2024 Financial Results
07 Nov 2024 //
BUSINESSWIRE
Amylyx Pharmaceuticals to Report Q3 2024 Results on Nov 7
04 Nov 2024 //
BUSINESSWIRE
Amylyx Announces Positive Results From Ph 2 Trial with Wolfram Syndrome
17 Oct 2024 //
BUSINESSWIRE
Amylyx Pharmaceuticals Hosts Webcast On Phase 2 HELIOS Study
15 Oct 2024 //
BUSINESSWIRE
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
28 Aug 2024 //
BUSINESSWIRE
Amylyx Publishes AMX0035 Data On Alzheimer`s Biomarkers
12 Aug 2024 //
BUSINESSWIRE
Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results
08 Aug 2024 //
BUSINESSWIRE
Amylyx Pharmaceuticals To Report Q2 2024 Results On August 8, 2024
05 Aug 2024 //
BUSINESSWIRE
Amylyx`s AMX0035 Gets EU Orphan Drug Status For Wolfram Syndrome
02 Aug 2024 //
BUSINESSWIRE
Amylyx Rebuilds Momentum Following Relyvrio Market Withdrawal
24 Jul 2024 //
BIOSPACE
After withdrawing ALS drug, Amylyx CEOs take lessons to rebuild the pipeline
10 Jul 2024 //
FIERCE BIOTECH
Amylyx Acquires Phase 3 GLP-1 Antagonist With FDA Breakthrough Status
10 Jul 2024 //
BUSINESSWIRE
Amylyx To Host Call On Avexitide Acquisition
09 Jul 2024 //
BUSINESSWIRE
Amylyx Seeks To Fill Relyvrio-Sized Hole With $35M GLP-1 Buy
24 Jun 2024 //
FIERCE BIOTECH
Amylyx to buy bankrupt Eiger`s experimental drug to treat low blood sugar
22 Jun 2024 //
REUTERS
Amylyx: Presenting At Goldman Sachs Healthcare Conference
04 Jun 2024 //
BUSINESSWIRE
Biogen, Ionis to discontinue development of experimental ALS drug
17 May 2024 //
REUTERS
Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results
09 May 2024 //
BUSINESSWIRE
Amylyx Pharmaceuticals: 2024 Bank of America Conference Presentation
08 May 2024 //
BUSINESSWIRE
Turbulence in Pharma: A Wave of Layoffs Sweeps Through the Industry
07 May 2024 //
BIOSPECTRUM ASIA
Amylyx To Report Q1 2024 Financial Results On May 9
02 May 2024 //
BUSINESSWIRE
Amylyx stock slips 6% after phase 2 rare disease data drop
11 Apr 2024 //
FIERCE BIOTECH
Amylyx Pharmaceuticals Reports HELIOS Trial Interim Data
10 Apr 2024 //
BUSINESSWIRE
Amylyx to Host Virtual Webcast to Discuss Data from Ph 2 HELIOS Study
08 Apr 2024 //
BUSINESSWIRE
Amylyx to pull failed ALS drug Relyvrio from market, cut 70% of staffers
05 Apr 2024 //
PRESS RELEASE
Amylyx Announces to Remove RELYVRIO®/ALBRIOZA™ from the Market
04 Apr 2024 //
BUSINESSWIRE
Shareholders of Amylyx Pharmaceuticals Should Contact The Gross Law Firm
26 Mar 2024 //
PR NEWSWIRE
Amylyx Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors
14 Mar 2024 //
BUSINESSWIRE
Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
09 Mar 2024 //
PRESS RELEASE
Amylyx Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035
08 Mar 2024 //
BUSINESSWIRE
Amylyx Pharmaceuticals Shareholder Alert
23 Feb 2024 //
PR NEWSWIRE
Amylyx Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
23 Feb 2024 //
BUSINESSWIRE
Amylyx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
22 Feb 2024 //
BUSINESSWIRE
Amylyx Pharmaceuticals to Present Updates on its AMX0114 and RELYVRIO® Programs
15 Feb 2024 //
BUSINESSWIRE
Amylyx Pharma to Report Fourth Quarter and Full Year 2023 Financial Results
15 Feb 2024 //
BUSINESSWIRE
Amylyx Pharmaceuticals Announces Completion of Enrollment in HELIOS
08 Feb 2024 //
BUSINESSWIRE
Amylyx Announces First Participant Dosed in Phase 3 Study of AMX0035
22 Dec 2023 //
BUSINESSWIRE
Amylyx Pharma Announces Publication of Data Showing the Effect of AMX0035
04 Dec 2023 //
BUSINESSWIRE
Amylyx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 Nov 2023 //
BUSINESSWIRE
Amylyx Pharma Appoints Camille L. Bedrosian, MD, as Chief Medical Officer
28 Nov 2023 //
BUSINESSWIRE
RELYVRIO® and AMX0114 Data to be Presented at 34th Symposium on ALS/MND
27 Nov 2023 //
BUSINESSWIRE
Amylyx to Participate at the 6th Annual Evercore ISI HealthCONx Conference
21 Nov 2023 //
BUSINESSWIRE
Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
BUSINESSWIRE
Amylyx to Report Third Quarter 2023 Financial Results on November 9, 2023
02 Nov 2023 //
BUSINESSWIRE
Amylyx Pharmaceuticals to Present Clinical Trial Design of ORION
19 Oct 2023 //
BUSINESSWIRE
Amylyx`s ALS drug Albrioza rebuffed by EU regulator—again
14 Oct 2023 //
FIERCE PHARMA
Amylyx Pharma Announces Publication of Survival Analysis Comparing CENTAUR
10 Oct 2023 //
BUSINESSWIRE
Amylyx Pharma Provides Update on Accès Compassionnel for AMX0035 in France
05 Oct 2023 //
BUSINESSWIRE
RELYVRIO® and AMX0114 Data to be Presented at 22nd Annual NEALS Meeting
02 Oct 2023 //
BUSINESSWIRE
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
05 Sep 2023 //
BUSINESSWIRE
Amylyx`s ALS drug Relyvrio continues to shine
11 Aug 2023 //
FIERCE PHARMA
Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
BUSINESSWIRE
Amylyx to Report Second Quarter 2023 Financial Results on August 10, 2023
03 Aug 2023 //
BUSINESSWIRE
Amylyx Pharmaceuticals to Host Virtual Webcast on AMX0035 PSP Program
12 Jul 2023 //
BUSINESSWIRE
Amylyx to appeal EMA panel recommendation against ALS drug
24 Jun 2023 //
ENDPTS
Amylyx Completes Negotiation Process with the pCPA for ALBRIOZA
15 Jun 2023 //
BUSINESSWIRE
Amylyx to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
06 Jun 2023 //
BUSINESSWIRE
Amylyx says European panel unlikely to endorse ALS drug
31 May 2023 //
REUTERS
